Krka Focuses On Extending Cardiovascular And Oncology Range
As Company Invests In Production And Laboratory Capacities
After reporting a profitable 2020, Slovenia’s Krka is looking to expand its cardiovascular and oncology portfolio, while adding to its diabetes and central nervous system range as well. The firm has also started manufacturing in China for the local market.
You may also be interested in...
Slovenia’s Krka saw business boom as it rushed to supply the demand created by the coronavirus pandemic, while reaping the benefits from its vertically integrated business model. CEO and president of the management board Jože Colarič has just been appointed for another six-year term.
The EMA’s CHMP has recommended granting pan-European marketing authorizations for Krka’s lenalidomide versions of Revlimid and Accord’s sunitinib rival to Sutent, as well as Xeris Pharmaceuticals’ glucagon hybrid rival to Glucagen.
The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs.